Biosig subsidiary neuroclear acquires license for a broad-spectrum anti-viral agent that may treat covid-19

Biosig subsidiary neuroclear acquires license for a broad-spectrum anti-viral agent that may treat covid-19. laboratory results demonstrate high level of activity against covid-19 in cell culture.biosig technologies inc - intends to pursue development of agent for treatment of covid-19 through fda-approved clinical trials..biosig technologies inc - expects that vicromax(tm) could be used alone or in a combination with other anti-viral agents or immune modulators.biosig - orally administered, broad-spectrum anti-viral agent vicromax demonstrated strong activity against covid-19 in cell cultures in lab testing.biosig technologies inc - appointed nick spring as ceo of viralclear and steve king as coo.biosig technologies inc - vicromax was added to a tissue culture assay for sars-co-2 coronavirus and an anti-viral effect was observed.biosig technologies - intends to develop vicromax and take it through clinical trials under a new neuroclear subsidiary, viralclear pharmaceuticals.
BSGM Ratings Summary
BSGM Quant Ranking